جست‌وجوی استاد و پژوهشگر

• Nutrition and Chronic Disease
• Cancer Epidemiology
• Obesity and Physical Activity
• +۳ مورد دیگر

Dagfinn Aune serves as a Research Fellow at the Department of Epidemiology and Biostatistics within the School of Public Health, Faculty of Medicine at Imperial College London. He concurrently holds positions as Associate Professor at Oslo New University College and Senior Researcher at the Cancer Registry of Norway in Oslo. His work centers on large-scale epidemiological investigations into diet, obesity, and chronic disease mechanisms across international populations. Education: PhD in Epidemiology, Norwegian University of Science and Technology (2016) MSc in Nutrition, University of Oslo (2008) Research interests focus on the interplay between dietary patterns, adiposity, physical activity, and smoking with chronic disease outcomes. His work examines how these factors influence cancer risk (particularly breast, gastrointestinal, and hematological malignancies), pregnancy complications, diabetes progression, and mortality across diverse populations. He employs systematic review methodologies and analyzes data from major cohorts including EPIC and Norwegian registries. Publication trends reveal consistent emphasis on obesity-cancer relationships, with recent work (2023-2025) expanding into metabolomic mediators, cardiometabolic interactions, and rare cancer epidemiology. His research frequently utilizes systematic reviews, meta-analyses, and multinational cohort studies to establish evidence for cancer prevention guidelines. Scientific Awards: No awards specified in source materials Advising and grant activity centers on major collaborative projects including the World Cancer Research Fund's Continuous Update Project, the EPIC study, and South American case-control research. While specific student mentorship isn't documented, his leadership in systematic review protocols suggests substantial training responsibilities. His grant portfolio includes funding from WCRF International and Norwegian research councils for large-scale epidemiological analyses. Labs and teams include the Centre for Translational Nutrition and Food Research at Imperial College London, where he collaborates with nutrition scientists and biostatisticians. He maintains active roles in the EPIC consortium and WCRF International's CUP Global Programme, coordinating multinational analyses of diet-cancer relationships through the Cancer Registry of Norway.

• Lymphoma
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• +۵ مورد دیگر

Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.

Mark R. Pittelkowمشاهده پروفایل

استاد

• Dermatology
• Cutaneous Lymphomas
• Photoprotection
• +۳ مورد دیگر

Mark R. Pittelkow is a Professor of Dermatology at the Mayo Clinic, holding a primary appointment as a Consultant in the Department of Dermatology. He completed his MD at Mayo Medical School and advanced training through Mayo Graduate School of Medicine and Northwestern University. His research focuses on cutaneous lymphomas, photoprotection, and skin cancer, with leadership roles in international guidelines (ISCL/EORTC). He contributes to clinical trials, medical education, and interdisciplinary research through affiliations like the Mayo Clinic Comprehensive Cancer Center and Regenerative Biotherapeutics. Education: MD (Mayo Medical School), MS (Biological Sciences, Northwestern), BA (Northwestern University). Research spans cutaneous lymphoma classification, immunology, and translational dermatology. Notable publications address staging systems for mycosis fungoides/Sezary syndrome and photoprotection strategies. His work integrates clinical practice with molecular mechanisms, such as JAK inhibitor responses in lichen planus. Labs/Teams: Collaborates with Mayo Clinic Cancer Center and interdisciplinary groups in immunotherapy and regenerative medicine. Supervises clinical trials and postdoctoral training programs.

Kristian Helinمشاهده پروفایل

استاد

• Cancer biology
• Epigenetics
• Stem cells
• +۵ مورد دیگر

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.

David Ericksonمشاهده پروفایل

استاد

• Global Health Technology
• Medical Diagnostics
• Microfluidics
• +۵ مورد دیگر

David Erickson is the SC Thomas Sze Director and Sibley College Professor at Cornell University's Sibley School of Mechanical and Aerospace Engineering. He also holds a joint professorship in the Division of Nutritional Sciences. His research focuses on global health technologies, medical diagnostics, microfluidics, photonics, nanotechnology, and energy systems. He previously served as Associate Dean of Engineering for Research and Graduate Programs. Erickson leads the NIH-funded PORTENT Center for Point-of-Care Technologies in Global Health and has co-founded companies like Dimensional Energy and VitaScan to commercialize diagnostic and energy technologies. Education: B.Sc., Mechanical Engineering, University of Alberta (1999) M.A.Sc., Mechanical Engineering, University of Toronto (2001) Ph.D., Mechanical Engineering, University of Toronto (2004) Postdoctoral Scholar, Electrical Engineering, California Institute of Technology (2005) Research Interests: Erickson’s work spans global health diagnostics , nanobio applications , and clean energy innovation . He develops portable medical devices for low-resource settings, including smartphone-integrated diagnostic tools for malaria, iron deficiency, and cancer. His lab also pioneers photothermal reactors for CO2 conversion into sustainable fuels. Key areas include: Point-of-care testing for infectious diseases and nutritional deficiencies Nanofluidic and optofluidic technologies for biomolecular analysis Solar-driven energy systems for carbon-neutral fuels Awards: Presidential Early Career Award for Scientists and Engineers (2011) Fellowships from the Optical Society, ASME, and Canadian Academy of Engineering Carbon X-Prize Finalist (2019) for Dimensional Energy’s CO2-to-fuel technology Grants & Industry Collaboration: Erickson’s research is funded by NIH, NSF, ARPA-E, DOE, and USAID. His lab’s innovations have spun off start-ups addressing global health and energy challenges. Notable projects include: - Portable cancer diagnostics in sub-Saharan Africa using mobile phone-based systems - Solar-powered CO2 conversion reactors tested in Wyoming and Arizona Labs & Teams: The Erickson Lab collaborates with the Cornell Atkinson Center for Sustainability and the McGovern Center for Entrepreneurship. Key initiatives include the PORTENT Center and the Dimensional Energy CO2-to-fuel project.

• Immunology
• Translational Immunology
• Computational Immunology
• +۴ مورد دیگر

Professor Mark Coles serves as Professor of Immunology and Lead for Industrial Strategy and Entrepreneurship at the Kennedy Institute of Rheumatology, University of Oxford, holding concurrent roles as Kennedy Trust Senior Research Fellow, Official Fellow at Reuben College, and Affiliate Faculty at the Wolfson Centre of Mathematical Biology. His interdisciplinary work bridges immunology, computational modeling, and translational research to accelerate therapies for immune-mediated inflammatory diseases. His academic journey began with a BSc in Microbiology from Cornell University (1992), followed by a PhD in Molecular and Cell Biology at UC Berkeley under David Raulet, and postdoctoral training with Dimitris Kioussis at the National Institute of Medical Research. At the University of York (2006-2017), he pioneered stromal immunology research and co-founded the York Computational Immunology Laboratory. Coles' research centers on stromal and systems immunology, with core expertise in stromal cell biology, inflammatory disease mechanisms, and mathematical modeling of immune responses. He champions 3Rs-based approaches (Replacement, Reduction, Refinement) to reduce animal testing through in silico models, integrating spatial single-cell biology with multi-scale computational frameworks to dissect immune function in human tissues. His 2025 publications reveal a cohesive research trajectory applying interdisciplinary methods across diverse disease contexts—from cardiac fibrosis and vaccine responses to arthritis pathogenesis and CAR-T cell therapy—unified by focus on stromal-immune crosstalk and quantitative modeling to identify therapeutic targets. Key honors include: Fellow of the Royal Society of Biology Kennedy Trust Senior Research Fellow As former Director of Graduate Studies (2017-2024) at the Kennedy Institute, Coles mentored numerous graduate students while co-leading major initiatives including the Arthritis Therapy Acceleration Program and Human Cell Atlas medicalization. His entrepreneurial impact spans three co-founded ventures: Simomics Ltd (in silico disease modeling), Lightox Ltd (phototherapy for oral cancer), and Mestag Therapeutics (fibroblast-targeted therapies for cancer/inflammation). He directs the Laboratory of Stromal and Systems Immunology and Oxford Mathematical Immunology Group, fostering collaborations with Christopher Buckley, Calliope Dendrou, and Eamonn Gaffney to develop Quantitative Systems Pharmacology models that translate mechanistic insights into patient therapies.

Itsik Pe'erمشاهده پروفایل

استاد

• Human Genetics
• Computational Biology
• Genomics
• +۳ مورد دیگر

Itsik Pe'er is a Full Professor and Vice-Chair in the Department of Computer Science at Columbia University's Fu Foundation School of Engineering & Applied Science, and holds a joint appointment as Professor of Systems Biology at the Vagelos College of Physicians and Surgeons. His research focuses on computational methods in human genetics, including genetic variation analysis, disease association studies, and algorithm development for genomic data. He leads the Itsik Pe'er Lab of Computational Genomics, which develops tools like Xplorigin, Germline, and SEACells to address challenges in genomics and medical research. His work spans machine learning applications in healthcare, microbiome analysis, and cancer genomics. Notable contributions include studies on hypertensive disorders in pregnancy, bias correction in predictive models, and the development of non-Euclidean learning libraries like Manify. Pe'er has advised students including Vladimir Vacic, Anat Kreimer, and Arthi Ramachandran, and collaborates on grants addressing genetic epidemiology and computational biology. His lab's location is in the Computer Science Building at Columbia's Morningside Campus.

Michael James Herdmanمشاهده پروفایل

دانشیار مهمان

• Patient Reported Outcomes
• Health Technology Assessment
• Outcomes Research
• +۳ مورد دیگر

Michael James Herdman is an Honorary Visiting Associate Professor at the National University of Singapore’s Saw Swee Hock School of Public Health. He serves as Head of Health Outcomes Research at the Office of Health Economics in London and Director of Insight Consulting & Research in Barcelona. His work focuses on patient-reported outcome (PRO) measures, including their development, validation, and application in healthcare evaluation. He has been a key member of the EuroQol Group for 25 years, contributing to initiatives like the EQ-5D-5L tool and pediatric health measurement standards. Education: MSc in Bioethics and Law from the University of Barcelona (1996–1998) and BSc Philosophy (Honors) from the University of Hull (1981–1985). Research Interests: Central to Herdman’s work are PRO measures, health technology assessment, and outcomes research, particularly in younger populations and pediatric health. He has authored over 150 peer-reviewed articles and book chapters, with notable contributions to cross-cultural adaptation of health instruments and systematic reviews on pediatric vaccines. Professional Activities: Provides consulting services to pharmaceutical companies and public health organizations. His work bridges academic research and practical applications in health economics and policy. Labs/Teams: Active in the EuroQol Group’s Executive Committee and Younger Populations Working Group, and leads Insight Consulting & Research.

Ross L. Levineمشاهده پروفایل

استاد

• Hematology
• Oncology
• Genetics
• +۴ مورد دیگر

Ross L. Levine, MD, is a distinguished Professor and Physician-Scientist at Memorial Sloan Kettering Cancer Center (MSKCC), holding the Edward P. Evans Endowed Chair for Myelodysplastic Syndromes (MDS). As Senior Vice President of Memorial Hospital’s Translational Research division, he leads groundbreaking work in hematologic malignancies, particularly leukemia and myeloproliferative neoplasms (MPNs). His research integrates clinical care with genomic and molecular studies to develop targeted therapies. Levine received his MD from Johns Hopkins University School of Medicine, followed by residency in Internal Medicine at Massachusetts General Hospital and fellowship in Hematology/Oncology at Dana-Farber Cancer Institute. Education: MD, Johns Hopkins University School of Medicine Residencies: Internal Medicine, Massachusetts General Hospital Fellowships: Hematology/Medical Oncology, Dana-Farber Cancer Institute Levine’s research focuses on the genetic and epigenetic drivers of myeloid cancers, including JAK-STAT pathway mutations in MPNs and AML. His team explores therapeutic strategies targeting CXCL8/CXCR2 signaling and clonal hematopoiesis. Key contributions include identifying JAK2 mutations in MPNs and advancing single-cell mutation analysis for clonal evolution studies. His clinical expertise includes treating patients with acute myeloid leukemia (AML), polycythemia vera, and myelofibrosis, performing bone marrow biopsies, and leading clinical trials for targeted therapies. Levine has pioneered translational research programs linking lab discoveries to patient care, emphasizing precision medicine. Awards & Honors: Pershing Square Sohn Prize (2014), Howard Hughes Medical Institute Early Career Award (2007), and multiple Leukemia & Lymphoma Society accolades. He holds leadership roles in professional societies, including co-chairing the American Society of Hematology’s 2016 Scientific Program. Levine’s lab, part of the Human Oncology & Pathogenesis Program (HOPP), collaborates with institutions globally. His work has been published in high-impact journals like Cancer Cell , Nature , and Blood , advancing understanding of cancer genetics and therapeutic innovation.

Karan S Dixitمشاهده پروفایل

استادیار

• Neuro-Oncology
• Brain Tumors
• Glioblastoma
• +۴ مورد دیگر

Karan S Dixit, MD is an Assistant Professor in the Department of Neurology at Northwestern University's Feinberg School of Medicine, specializing in neuro-oncology and serving as Fellowship Director for the education program. His educational background includes: MD from Louisiana State University (2011) Internal Medicine Internship at University of Illinois at Chicago (2012) Neurology Residency and Chief Medical Resident at University of Illinois at Chicago (2015) Neuro-Oncology Fellowship at Northwestern University McGaw Medical Center (2016) He maintains board certification in Neurology (American Board of Psychiatry and Neurology) and Neuro-Oncology (United Council for Neurologic Subspecialties). Dr. Dixit's research centers on CNS lymphoma, lower-grade gliomas, and glioblastoma, with emphasis on novel therapies for treatment resistance. He investigates biomarkers for disease monitoring and explores neurocognitive decline mechanisms related to neural connectivity changes during CNS cancer treatment. His work bridges clinical neurology with translational oncology through molecular diagnostics and therapeutic innovation. His 2025 publications reveal three critical research trajectories: molecular characterization of glioma mutations (TERT/IDH), liquid biopsy applications for CNS lymphoma diagnosis, and repurposing antiseizure drugs with antineoplastic potential. These studies collectively advance precision medicine approaches for treatment-resistant CNS malignancies. Professional recognition includes: John A Kessler Teaching Award (2022, 2019) NeuroNEXT Fellow (2020) Society of Neuro-Oncology Clinical Trials Course (2019) University of Illinois Teaching Excellence Awards (2014-2015) As Fellowship Director, Dr. Dixit mentors neuro-oncology trainees while leading three active clinical trials: Vorasidenib/Pembrolizumab for IDH-mutant glioma (NCT05484622), NX-5948 BTK degrader for CNS lymphoma (NCT05131022), and emavusertib for relapsed PCNSL (NCT03328078). His industry collaborations include Bluprint Oncology Concepts and Servier Pharmaceuticals for therapeutic development. He maintains active membership in the Feinberg Academy of Medical Educators, American Neurological Association, American Academy of Neurology (Neuro-Oncology Section), American Society of Clinical Oncology, and Society of Neuro-Oncology, collaborating through Northwestern Medicine's Robert H. Lurie Comprehensive Cancer Center and Clinical and Translational Sciences Institute.

KEMAL OZAN LÜLEمشاهده پروفایل

استادیار

• Internal Medicine
• Endocrinology
• Gastroenterology
• +۶ مورد دیگر

KEMAL OZAN LÜLE is an Assistant Professor at Gaziantep University, Faculty of Medicine, Department of Internal Medicine , with an email contact at ozan@gantep.edu.tr . He holds an ORCID identifier and is registered in the YÖK Academic Information System. Education: Medical License from Dokuz Eylül University (2009–2016), Medical Specialization from Gaziantep University (2017–2021). Professional Experience: Specialist at Gaziantep Abdulkadir Yuksel State Hospital (2021–2024), General Practitioner at Arapgir Ali Özge State Hospital (2016–2017). Administrative Roles: Member of Measurement and Evaluation Board (2024), Internal Medicine Internship Education Coordinator (2024), English Medicine Assistant Coordinator (2024). His research focuses on Internal Medicine , with emphasis on Diabetes , Fatty Liver Disease , Neurocognitive Effects of diabetes treatments, Cancer Development linked to food preparation, Irritable Bowel Syndrome , and Adrenal Incidentaloma . Book Chapters: Development and Natural Course of Diabetic Fatty Liver Disease (2025), Effects of Pharmacological Agents on Neurological Functions (2023), Food Preparation Methods and Cancer (2023). He has co-authored multiple proceedings papers on topics including Temporal Arthritis , Lymphoma , Behçet’s Disease , and Fahr Syndrome , presented at national and international conferences.

Kenneth Hoehnمشاهده پروفایل

استادیار

• Computational Immunology
• Evolutionary Biology
• B Cell Biology
• +۵ مورد دیگر

Kenneth Hoehn is an Assistant Professor in the Department of Biomedical Data Science at the Geisel School of Medicine, Dartmouth College. As a computational immunologist with expertise in evolutionary biology, he develops computational evolutionary approaches to trace cellular lineages, particularly B cells, in contexts such as infection, vaccination, cancer, and autoimmune diseases. His research focuses on understanding adaptive immunity in conditions like COVID-19 Food allergies Myasthenia gravis through collaborations with experimental teams. Key projects include: Phylogenetic modeling of B cell responses Evolutionary signatures in immune repertoires Tracking B cell dissemination in autoimmune diseases Epigenetic regulation of memory B cells Recent publications highlight trends in single-cell immunology , phylogenetic inference , and computational tools for analyzing B cell dynamics. His lab at Dartmouth integrates evolutionary genetics with high-resolution immune profiling.

• Immunodeficiency Diseases
• Actin Regulators in Immune Cells
• Autoimmunity
• +۳ مورد دیگر

Lisa Westerberg is a Professor of Experimental Immunology at the Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet. Her research focuses on understanding how compromised immune systems lead to immunodeficiency, autoimmunity, and hematological cancers, particularly studying the role of actin regulators in immune cell function. She leads the 'Immunodeficiency Diseases – Lisa Westerberg Group' and collaborates internationally with institutions like Harvard Medical School and the University College London. Education: PhD in Cell and Molecular Biology from Karolinska Institutet (2003), postdoc at Harvard Medical School (2009). Affiliations: Department of Microbiology, Tumor and Cell Biology; WASPSTINGS network (STINT-funded); Swedish Society for Immunology (Treasurer). Research Interests: Immunodeficiency diseases, actin cytoskeleton dynamics in immune cells, cancer immunology, and space immunology. Her lab investigates how genetic mutations in actin regulators affect immune cell communication, migration, and genomic stability. Recent projects include studying immune system adaptation in microgravity and developing therapies targeting actin regulators in cancer. Articles Trends: Recent work highlights immune cell adaptations in space environments, therapeutic modulation of actin pathways, and clonal evolution in lymphomas. Over 15 articles since 2020 explore mechanisms linking immune dysfunction to cancer and immunodeficiency. Awards: Ragnar Söderberg Fellowship, ERC Starting Grant (2019), Wallenberg Academy Fellow. Funding: Swedish Research Council, Knut och Alice Wallenberg Foundation, EU grants. Advising & Grants: Supervised over 40 students (PhD, Master’s, undergrad) since 2010. Active in training programs like the Amgen Scholars initiative. Collaborates with global teams on projects funded by VR, NIH, and international partnerships. Labs/Teams: Leads the core Immunodeficiency Diseases Group and collaborates with the Dosenovic Lab (focusing on B cell vaccine development). The group uses CRISPR, high-resolution microscopy, and single-cell sequencing to study immune mechanisms.

Preet Singhمشاهده پروفایل

استاد

• Corrosion Science
• Electrochemistry
• Metals and Alloys
• +۵ مورد دیگر

Preet Singh is a Professor and Associate Chair for Graduate Studies in the School of Materials Science and Engineering at Georgia Tech, with affiliations to the College of Engineering. His research focuses on corrosion science, electrochemistry, and environmental degradation of materials, particularly metals and alloys. Prior to joining Georgia Tech in 2003, he was a faculty member at the Institute of Paper Science and Technology (IPST), where he investigated corrosion issues in the pulp and paper industry. Professor Singh's work explores fundamental mechanisms of material degradation in industrial environments, aiming to develop mitigation strategies against environment-induced failures. Key research areas include corrosion fatigue, hydrogen embrittlement, stress corrosion cracking, and oxidation behavior. His group employs experimental approaches to study material reliability under varying chemical and mechanical conditions. Recent publications demonstrate interdisciplinary collaboration across oncology, agriculture, and energy systems, reflecting broad applications of materials science principles. Research trends show increased focus on biomedical materials and sustainable technologies alongside core corrosion studies. Professor Singh advises graduate students including Abdullah Alzubail, Yousif Al Rabie, Sai Shreeya, Yara, and Sean Li. He directs the Corrosion and Materials Reliability Laboratory (CMCRL), which partners with industry to solve practical engineering challenges related to material performance.

John F. Rudgeمشاهده پروفایل

استاد

• Geophysics
• Geochemistry
• Petrology
• +۴ مورد دیگر

John F. Rudge is a Professor of Geodynamics at the Bullard Laboratories, Department of Earth Sciences, University of Cambridge , and a Fellow and Dean of Trinity College. His research focuses on the dynamics of Earth's interior, including mantle convection, magma transport, and the geochemical evolution of the planet. He employs continuum mechanics, numerical analysis, and statistical methods to address questions about melt dynamics, mantle heterogeneity, and the surface expressions of geophysical processes. Education includes a mathematics undergraduate degree and a PhD in Earth Sciences and Applied Mathematics from Cambridge. He held postdoctoral positions at institutions like ETH Zürich, Yale, and Columbia University before joining Cambridge as a University Lecturer in 2010 and being promoted to Professor in 2022. Key research areas include: Transport of melts and volatiles in the mantle Evolution of Earth's interior from accretion to present Dynamic topography and inner core dynamics Publications span over two decades, with recent works addressing melt rheology, mantle mineralogy, and interdisciplinary applications in oncology. He has supervised numerous PhD students and postdocs, including David Rees Jones, Isarapong Eksinchol, and Laura Alisic. Awards include the Philip Leverhulme Prize and Geological Society President’s Award. Teaching responsibilities include courses on geophysics, magma dynamics, and supervisions in Natural Sciences at Trinity College. Research tools include finite element modeling and collaborations with computational scientists.